Tags

Type your tag names separated by a space and hit enter

Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.
Vaccine. 2011 Sep 02; 29(38):6606-13.V

Abstract

SARS-CoV was the cause of the global pandemic in 2003 that infected over 8000 people in 8 months. Vaccines against SARS are still not available. We developed a novel method to produce high levels of a recombinant SARS virus-like particles (VLPs) vaccine containing the SARS spike (S) protein and the influenza M1 protein using the baculovirus insect cell expression system. These chimeric SARS VLPs have a similar size and morphology to the wild type SARS-CoV. We tested the immunogenicity and protective efficacy of purified chimeric SARS VLPs and full length SARS S protein vaccines in a mouse lethal challenge model. The SARS VLP vaccine, containing 0.8 μg of SARS S protein, completely protected mice from death when administered intramuscular (IM) or intranasal (IN) routes in the absence of an adjuvant. Likewise, the SARS VLP vaccine, containing 4 μg of S protein without adjuvant, reduced lung virus titer to below detectable level, protected mice from weight loss, and elicited a high level of neutralizing antibodies against SARS-CoV. Sf9 cell-produced full length purified SARS S protein was also an effective vaccine against SARS-CoV but only when co-administered IM with aluminum hydroxide. SARS-CoV VLPs are highly immunogenic and induce neutralizing antibodies and provide protection against lethal challenge. Sf9 cell-based VLP vaccines are a potential tool to provide protection against novel pandemic agents.

Authors+Show Affiliations

Novavax Inc., 9920 Belward Campus Drive, Rockville, MD 20850, United States. yliu@novavax.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

21762752

Citation

Liu, Ye V., et al. "Chimeric Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) S Glycoprotein and Influenza Matrix 1 Efficiently Form Virus-like Particles (VLPs) That Protect Mice Against Challenge With SARS-CoV." Vaccine, vol. 29, no. 38, 2011, pp. 6606-13.
Liu YV, Massare MJ, Barnard DL, et al. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV. Vaccine. 2011;29(38):6606-13.
Liu, Y. V., Massare, M. J., Barnard, D. L., Kort, T., Nathan, M., Wang, L., & Smith, G. (2011). Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV. Vaccine, 29(38), 6606-13. https://doi.org/10.1016/j.vaccine.2011.06.111
Liu YV, et al. Chimeric Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) S Glycoprotein and Influenza Matrix 1 Efficiently Form Virus-like Particles (VLPs) That Protect Mice Against Challenge With SARS-CoV. Vaccine. 2011 Sep 2;29(38):6606-13. PubMed PMID: 21762752.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV. AU - Liu,Ye V, AU - Massare,Michael J, AU - Barnard,Dale L, AU - Kort,Thomas, AU - Nathan,Margret, AU - Wang,Lei, AU - Smith,Gale, Y1 - 2011/07/14/ PY - 2011/02/16/received PY - 2011/03/22/revised PY - 2011/06/29/accepted PY - 2011/7/19/entrez PY - 2011/7/19/pubmed PY - 2011/12/13/medline SP - 6606 EP - 13 JF - Vaccine JO - Vaccine VL - 29 IS - 38 N2 - SARS-CoV was the cause of the global pandemic in 2003 that infected over 8000 people in 8 months. Vaccines against SARS are still not available. We developed a novel method to produce high levels of a recombinant SARS virus-like particles (VLPs) vaccine containing the SARS spike (S) protein and the influenza M1 protein using the baculovirus insect cell expression system. These chimeric SARS VLPs have a similar size and morphology to the wild type SARS-CoV. We tested the immunogenicity and protective efficacy of purified chimeric SARS VLPs and full length SARS S protein vaccines in a mouse lethal challenge model. The SARS VLP vaccine, containing 0.8 μg of SARS S protein, completely protected mice from death when administered intramuscular (IM) or intranasal (IN) routes in the absence of an adjuvant. Likewise, the SARS VLP vaccine, containing 4 μg of S protein without adjuvant, reduced lung virus titer to below detectable level, protected mice from weight loss, and elicited a high level of neutralizing antibodies against SARS-CoV. Sf9 cell-produced full length purified SARS S protein was also an effective vaccine against SARS-CoV but only when co-administered IM with aluminum hydroxide. SARS-CoV VLPs are highly immunogenic and induce neutralizing antibodies and provide protection against lethal challenge. Sf9 cell-based VLP vaccines are a potential tool to provide protection against novel pandemic agents. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/21762752/Chimeric_severe_acute_respiratory_syndrome_coronavirus__SARS_CoV__S_glycoprotein_and_influenza_matrix_1_efficiently_form_virus_like_particles__VLPs__that_protect_mice_against_challenge_with_SARS_CoV_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(11)01005-X DB - PRIME DP - Unbound Medicine ER -